Heron Therapeutics (HRTX) to Release Earnings on Monday

Heron Therapeutics (NASDAQ:HRTX) is anticipated to issue its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $42.19 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 8:30 AM ET.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The company had revenue of $34.71 million during the quarter, compared to analysts’ expectations of $36.72 million. Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX traded up $0.02 during trading on Monday, hitting $0.51. 252,351 shares of the stock traded hands, compared to its average volume of 2,467,480. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. The company has a market cap of $96.91 million, a price-to-earnings ratio of -2.84 and a beta of 1.65. The company has a fifty day moving average price of $0.49 and a two-hundred day moving average price of $0.87. Heron Therapeutics has a 52-week low of $0.38 and a 52-week high of $1.88.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HRTX shares. Zacks Research lowered shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. HC Wainwright lowered their target price on shares of Heron Therapeutics to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen cut Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $2.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HRTX. The Manufacturers Life Insurance Company increased its stake in Heron Therapeutics by 5.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock worth $499,000 after buying an additional 11,716 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Heron Therapeutics during the second quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Heron Therapeutics by 19.3% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 13,544 shares during the last quarter. Advisory Services Network LLC lifted its position in shares of Heron Therapeutics by 2,383.4% in the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 18,114 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Heron Therapeutics in the second quarter valued at approximately $43,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.